Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811501 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4815197 | 0.84 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4812759 | 0.84 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4810685 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4809914 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4810771 | 0.80 | TSHR (0.43) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4809337 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4804622 | 0.78 | TSHR (0.46) | ALDH1A1SMN1; SMN2MAPTPOLBTP53 | |
| SCHEMBL4859975 | 0.76 | TSHR (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL4808688 | 0.76 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20050267173-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-12-01 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ALDH1A1 2580/4885SMN1; SMN2 3725/4885RAB9A 2685/4885 |
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | ALDH1A1 1913/4885SMN1; SMN2 3179/4885RAB9A 3346/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ALDH1A1 1335/4885SMN1; SMN2 3761/4885RAB9A 2314/4885 |
| US-20050267173-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ALDH1A1 2580/4885SMN1; SMN2 3725/4885RAB9A 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.